Wall Street brokerages expect Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) to announce earnings of ($0.43) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Sienna Biopharmaceuticals’ earnings. Sienna Biopharmaceuticals reported earnings of ($1.00) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 57%. The firm is expected to report its next earnings report on Thursday, August 8th.
Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Sienna Biopharmaceuticals.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last issued its earnings results on Wednesday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter.
Institutional investors and hedge funds have recently modified their holdings of the business. Paloma Partners Management Co bought a new position in Sienna Biopharmaceuticals during the fourth quarter worth about $28,000. Dimensional Fund Advisors LP bought a new position in shares of Sienna Biopharmaceuticals during the 4th quarter valued at about $36,000. Rhumbline Advisers lifted its holdings in shares of Sienna Biopharmaceuticals by 52.9% during the 4th quarter. Rhumbline Advisers now owns 19,377 shares of the company’s stock valued at $45,000 after purchasing an additional 6,702 shares in the last quarter. LLBH Private Wealth Management LLC bought a new position in shares of Sienna Biopharmaceuticals during the 1st quarter valued at about $49,000. Finally, Raymond James & Associates bought a new position in shares of Sienna Biopharmaceuticals during the 4th quarter valued at about $54,000. Hedge funds and other institutional investors own 51.32% of the company’s stock.
Shares of SNNA opened at $1.07 on Thursday. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 0.90. Sienna Biopharmaceuticals has a 1 year low of $0.94 and a 1 year high of $18.05. The stock has a market cap of $31.76 million, a price-to-earnings ratio of -0.30 and a beta of 3.49.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Story: How to calculate compound interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.